ITCI - Intra-Cellular Therapies GAAP EPS of -$0.57 beats by $0.25 revenue of $71.9M beats by $5.9M
- Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q3 GAAP EPS of -$0.57 beats by $0.25 .
- Revenue of $71.9M (+223.7% Y/Y) beats by $5.9M .
- Cash, cash equivalents, restricted cash and investment securities totaled $630.5 million at September 30, 2022, compared to $413.7 million at December 31, 2021.
For further details see:
Intra-Cellular Therapies GAAP EPS of -$0.57 beats by $0.25, revenue of $71.9M beats by $5.9M